46 related articles for article (PubMed ID: 4577503)
1. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance.
Van Scott EJ; Kalmanson JD
Cancer; 1973 Jul; 32(1):18-30. PubMed ID: 4577503
[No Abstract] [Full Text] [Related]
2. Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations.
Crimp C; Gangal A; Tarabadkar ES; Shinohara MM
Cancer Manag Res; 2022; 14():3271-3279. PubMed ID: 36444357
[TBL] [Abstract][Full Text] [Related]
3. Interventions for mycosis fungoides.
Valipour A; Jäger M; Wu P; Schmitt J; Bunch C; Weberschock T
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD008946. PubMed ID: 32632956
[TBL] [Abstract][Full Text] [Related]
4. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel.
Denis D; Beneton N; Laribi K; Maillard H
Cancer Manag Res; 2019; 11():2241-2251. PubMed ID: 30962713
[TBL] [Abstract][Full Text] [Related]
5. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.
Liner K; Brown C; McGirt LY
Drug Des Devel Ther; 2018; 12():241-254. PubMed ID: 29440874
[TBL] [Abstract][Full Text] [Related]
6. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
Lessin SR; Duvic M; Guitart J; Pandya AG; Strober BE; Olsen EA; Hull CM; Knobler EH; Rook AH; Kim EJ; Naylor MF; Adelson DM; Kimball AB; Wood GS; Sundram U; Wu H; Kim YH
JAMA Dermatol; 2013 Jan; 149(1):25-32. PubMed ID: 23069814
[TBL] [Abstract][Full Text] [Related]
7. New concepts in the management of mycosis fungoides.
Fuks Z; Bagshaw MA; Farber EM
West J Med; 1974 Feb; 120(2):150-1. PubMed ID: 18747333
[No Abstract] [Full Text] [Related]
8. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
Pai VB; Nahata MC
Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous T cell lymphomas.
Bunn PA
BMJ; 1994 Feb; 308(6928):551-2. PubMed ID: 8031362
[No Abstract] [Full Text] [Related]
10. Treatment of cutaneous T-cell lymphoma with a new aromatic retinoid (Ro 10-9359).
Claudy AL; Delomier Y; Hermier C
Arch Dermatol Res; 1982; 273(1-2):37-42. PubMed ID: 6985201
[TBL] [Abstract][Full Text] [Related]
11. The immunological profile of mycosis fungoides.
Jensen JR; Thestrup-Pedersen K; Ahrons S; Zachariae H
Clin Exp Immunol; 1982 Nov; 50(2):397-405. PubMed ID: 6983938
[TBL] [Abstract][Full Text] [Related]
12. Hypersensitivity reactions from antineoplastic agents.
Weiss RB; Baker JR
Cancer Metastasis Rev; 1987; 6(3):413-32. PubMed ID: 3319275
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse.
Dorr RT; Soble M; Alberts DS
Cancer Chemother Pharmacol; 1988; 22(4):299-302. PubMed ID: 3168143
[TBL] [Abstract][Full Text] [Related]
14. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides.
Kaltoft K; Bisballe S; Dyrberg T; Boel E; Rasmussen PB; Thestrup-Pedersen K
In Vitro Cell Dev Biol; 1992 Mar; 28A(3 Pt 1):161-7. PubMed ID: 1582990
[TBL] [Abstract][Full Text] [Related]
15. Immune response to primary immunization with brucella antigen in mycosis fungoides.
Thulin H
Arch Dermatol Forsch; 1975; 251(4):311-5. PubMed ID: 1119849
[TBL] [Abstract][Full Text] [Related]
16. Weekly total skin electron beam therapy for mycosis fungoides and other cutaneous lymphomata: further experience.
D'Angio GJ; Nisce LZ; Kim JH
Br J Cancer Suppl; 1975 Mar; 2():379-85. PubMed ID: 810154
[TBL] [Abstract][Full Text] [Related]
17. The treatment of mycosis fungoides and related conditions with particular emphasis on electron therapy.
Szur L
Br J Cancer Suppl; 1975 Mar; 2():368-78. PubMed ID: 810153
[TBL] [Abstract][Full Text] [Related]
18. Absence of leukocyte-migration inhibitory factor in serum from patients with mycosis fungoides.
Thulin H
Arch Dermatol Res (1975); 1976 Dec; 257(2):157-61. PubMed ID: 795384
[TBL] [Abstract][Full Text] [Related]
19. Management of mycosis fungoides.
du Vivier A
J R Soc Med; 1979 Oct; 72(10):717-8. PubMed ID: 552428
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
